Active Surveillance of Papillary Thyroid Cancer: Tumor Volume Kinetics with Dr. Morris
We are honored to have Dr. Luc Morris present "Active Surveillance of Papillary Thyroid Cancer Frequency and Time Course of 6 Most Common Tumor Volume Kinetic Patterns." Dr. Eyal Robenshtok joins as the featured expert discussant. 0:00 Webinar 0:37 Dr. Morris presents Incidence of Thyroid Cancer The incidence of thyroid cancer, primarily driven by a three-fold increase in papillary thyroid cancer, has risen significantly. However, this increase in diagnoses has not been accompanied by a corresponding rise in mortality rates, which have remained relatively low. Interestingly, while the number of thyroid cancer diagnoses has surged, the actual number of thyroid cancer cases and associated deaths has remained stable. This phenomenon suggests that the apparent rise in thyroid cancer is not an epidemic of the disease itself but rather an increase in the rate of diagnosis, including the identification of previously undiagnosed cases. Gender Disparities in Diagnosis The incidence of thyroid cancer is three times higher in women than in men. Despite the similar prevalence of thyroid cancer in autopsy studies for both sexes, women are diagnosed three times more frequently than men. For every detected case of papillary thyroid carcinoma (PTC), there are an estimated 1,000 undiagnosed cases, referred to as occult PTC. Overdiagnosis in Thyroid Cancer Overdiagnosis in cancer refers to the identification of cancers that would not progress to cause symptoms or death. In South Korea, thyroid cancer treatments have reported a 2% incidence of recurrent laryngeal nerve injury and an 11% incidence of permanent hypoparathyroidism. Active Surveillance Origins & Guidelines Active surveillance of small PTCs originated in Japan, where data demonstrated that the majority of small PTCs do not grow significantly under close observation. In 2015, the American Thyroid Association (ATA) guidelines recommended that active surveillance could be considered an alternative to immediate surgery for low-risk PTC. Criteria for Surgical Intervention Reasons for opting for surgical intervention include tumor growth greater than 3mm, significant radiographic changes, or patient preference. Under active surveillance, the cumulative incidence of PTC growth over ten years shows a 20-25% increase in diameter by 3 mm and a 72% increase in volume. The risk of lymph node metastasis during active surveillance is approximately 3.3%, compared to 5% following total thyroidectomy. Kinetic Patterns of PTC Growth The kinetic patterns of growth indicate that the majority of papillary thyroid carcinoma (PTC) cases remain indolent, with 84% showing no significant growth at 5 years and 83% at 10 years. Anxiety Levels in Patients Surgery does not alleviate anxiety in thyroid cancer patients. Those who undergo immediate surgery experience higher levels of , which tend to increase over time. In contrast, patients who opt for active surveillance exhibit lower levels of anxiety, which decrease over time. 28:35 Dr. Robenshtok presents Prevalence of Occult PTC Occult papillary thyroid carcinoma (PTC) is present in approximately 5-10% of the general population. Decisions regarding lobectomy or active surveillance should ideally be made before a fine-needle aspiration (FNA) biopsy. In practice, patients with small suspicious nodules on ultrasound may rush to undergo biopsies; however, an FNA for nodules smaller than 1 cm is equivalent to active surveillance. Requirements for Active Surveillance Active surveillance requires an ideal patient, an ideal location, and a dedicated team of physicians. Follow-up involves a flexible ultrasound schedule based on observed changes, with growth monitored alongside periods of quiescence. The incidence of new lymph node metastasis over 10 years is approximately 3.3% and is not related to the tumor's kinetic pattern. Quality of Life & Clinical Challenges Patients who choose active surveillance generally experience a positive quality of life. For clinicians, active surveillance can be more labor-intensive, and there is no evidence of successful malpractice litigation associated with this approach in cancer treatment. Currently, no tool can definitively predict whether a lesion will grow or remain stable, highlighting the need for improved predictive tools in the future. 49:04 Discussion with Q&A ** Check out our other programs! ** The THANC Guide https://thancguide.org/ TIRO: Thyroid Int'l Recommendations Online https://tiro.expert/ ** Follow us on Twitter! ** @thancfoundation - https://shorturl.at/puwS0 THANC on FB - https://shorturl.at/svNY4

Radioiodine Avidity in Thyroid Cancer with Dr. Juhlin

Management and Follow-up of High Risk Patients with Papillary Thyroid Cancer

Thyroid nodules and Tirads

The History of Thyroid Cancer Treatment Over the Decades // Fireside Chat

You Cannot Heal Your THYROID If You Do These 10 Things Daily

Seniors No 1 Oncologist Reveals Foods to Starve Cancer Cells Naturally After 50! |Dr. William Li

Adjuvant Durvalumab and the Future of Early-Stage NSCLC

TSH Suppression & Survival in DTC with Dr. Klubo-Gwiezdzinska

Dr Michael Tuttle 🔹Thyroid Cancer 🔹Active Surveillance HD 1080p

Active Surveillance of Thyroid Cancer | James Wu, MD | UCLAMDChat

2026 Type 2 Diabetes Management Algorithm (Episode 2)

The Year in Thyroidology: Key Updates with Dr. Davies

Ivermectin to Treat Cancer? Get the FACTS

Love Island’s Demi Jones Opens Up About Her Thyroid Cancer Diagnosis | Good Morning Britain

Professor Dr. Susan Mandel, Updates to the American Thyroid Association thyroid nodules guidelines

3.48 The Predictive Value of High Tumor Mutational Burden with Dr. Luc Morris

Choosing Surveillance Over Surgery: Thyroid Cancer Treatments Revolutionized

How I Got My Cancer Diagnosis | Elise’s Multiple Myeloma Story (1 of 4) | The Patient Story

Papillary and Follicular Thyroid Cancer. When and How To Treat, or Watch and Wait. Dr. Busaidy.

